新型コロナワクチンの有効性に関する研究

1.

Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Masuda S, Osawa R, Hosokawa N, Nakashima K, Kamura H, Imura H, Inoue H, Matsuzaka S, Sugimoto Y, Kuwamitsu O, Motohashi I, Morikawa T, Oda R, Hoshina Y, Matono T, Teshigahara O, Sando E, Asami S, Kudo S, Akizuki N, Muto Y, Hayakawa T, Kishaba T, Ohara Y, Kubo Y, Suzuki M, Morimoto K. Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). DOI:10.1080/14760584.2024.2310807, Expert Rev Vaccines.23:213-225, 2024

2.

Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Ito T, Ikeda H, Kamura H, Motohashi I, Kimura Y, Komino M, Arai H, Kuwamitsu O, Akuzawa N, Sando E, Morikawa T, Imura H, Inoue H, Hayakawa T, Teshigahara O, Ohara Y, Suzuki M, Morimoto K*. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). DOI: 10.1080/14760584.2023.2188950, Expert Rev Vaccines. 22:288-298, 2023

3.

Maeda H,N, Igarashi A, Ishida M, Suami K, Yagiuchi A, Kimura Y, Komino M, Arai H, Morikawa T, Motohashi I, Miyazawa R, Moriyama T, Kamura H, Terada M, Kuwamitsu O, Hayakawa T, Sando E, Ohara Y, Teshigahara O, Suzuki M, Morimoto K , Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS). DOI: 10.1093/cid/ciac292, Clin Infect Dis. 75:1971-1979, 2022

APSG-J研究

1.

Wakabayashi T, Hamaguchi S, Morimoto K; Adult Pneumonia Study Group – Japan. Clinically defined aspiration pneumonia is an independent risk factor associated with long-term hospital stay: a prospective cohort study. DOI: 10.1186/s12890-023-02641-y, BMC Pulm Med.23:351, 2023

2.

Dhoubhadel BG, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Ishida M, Hamaguchi S, Aoshima M, Yasunami M, Ariyoshi K, Morimoto K; Adult Pneumonia Study Group-Japan (APSG-J). High prevalence of multiple serotypes of pneumococci in patients with pneumonia and their associated risk factors. DOI: 10.1136/thoraxjnl-2021-217979, Thorax. 77:1121-1130, 2022

3.

Sando E, Suzuki M, Ishida M, Yaegashi M, Aoshima M, Ariyoshi K, Morimoto K. Definitive and Indeterminate Pseudomonas aeruginosa Infection in Adults with Community-acquired Pneumonia. DOI: 10.1513/AnnalsATS.201906-459OC, Ann Am Thorac Soc.18:1475-1481, 2021

4.

Nemoto M, Nakashima K, Noma S, Matsue Y, Yoshida K, Matsui H, Shiraishi A, Ishifuji T, Morimoto K, Ariyoshi K, Aoshima M. Prognostic value of chest computed tomography in community-acquired pneumonia patients. DOI: 10.1183/23120541.00079-2020, ERJ Open Res. 6:00079-2020;2020

5.

Hasegawa S, Sada R, Yaegashi M, Morimoto K, Mori T; Adult Pneumonia Study Group-Japan. 1g versus 2 g daily intravenous ceftriaxone in the treatment of community onset pneumonia - a propensity score analysis of data from a Japanese multicenter registry. DOI: 10.1186/s12879-019-4552-8, BMC Infect Dis.19:1079, 2019

6.

Hasegawa S, Shiraishi A, Yaegashi M, Hosokawa N, Morimoto K, Mori T. Ceftriaxone versus ampicillin/sulbactam for the treatment of aspiration-associated pneumonia in adults. DOI: 10.2217/cer-2019-0041, J Comp Eff Res. 8:1275-1284, 2019

7.

Suzuki M, Katsurada N, Le MN, Kaneko N, Yaegashi M, Hosokawa N, Otsuka Y, Aoshima M, Yoshida LM, Morimoto K. Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan. DOI: 10.1016/j.vaccine.2018.04.037, Vaccine. 36:2960-2967, 2018

8.

Hamaguchi S, Suzuki M, Sasaki K, Abe M, Wakabayashi T, Sando E, Yaegashi M, Morimoto S, Asoh N, Hamashige N, Aoshima M, Ariyohsi K, Morimoto K; Adult Pneumonia Study Group-Japan. Six underlying health conditions strongly influence mortality based on pneumonia. DOI: 10.1186/s12890-018-0648-y, BMC Pulm Med. 18:88, 2018

9.

Kakiuchi S, Suzuki M, Dhoubhadel BG, Furumoto A, Ito H, Matsuki K, Tsuchihashi Y, Asoh N, Yasunami M, Ariyoshi K, Morimoto K. Accuracy of High-Throughput Nanofluidic PCR-Based Pneumococcal Serotyping and Quantification Assays Using Sputum Samples for Diagnosing Vaccine Serotype Pneumococcal Pneumonia: Analyses by Composite Diagnostic Standards and Bayesian Latent Class Models. DOI: 10.1128/JCM.01874-17, J Clin Microbiol. 56: pii: e01874-17, 2017

10.

Katsurada N, Suzuki M, Aoshima M, Yaegashi M, Ishifuji T, Asoh N, Hamashige N, Abe M, Ariyoshi K, Morimoto K; Adult Pneumonia Study Group-Japan. The impact of virus infections on pneumonia mortality is complex in adults: a prospective multicentre observational study. DOI: 10.1186/s12879-017-2858-y, BMC Infect Dis. 17:755, 2017

11.

Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, Ishida M, Hamaguchi S, Aoshima M, Ariyoshi K, Morimoto K*; Adult Pneumonia Study Group-Japan (APSG-J). Serotype -specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. DOI: 10.1016/S1473-3099(17)30049-X, Lancet Infect Dis. 17:313-321, 2017

12.

Ishifuji T, Sando E, Kaneko N, Suzuki M, Kilgore PE, Ariyoshi K, Morimoto K, Hosokawa N, Yaegashi M, Aoshima M; Adult Pneumonia Study Group - Japan (APSG-J). Recurrent pneumonia among Japanese adults: disease burden and risk factors. DOI: 10.1186/s12890-016-0359-1, BMC Pulm Med. 17:12, 2017

13.

Morimoto K, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Hamashige N, Abe M, Aoshima M, Ariyoshi K; on behalf of the Adult Pneumonia Study Group – Japan (APSG-J), The burden and etiology of community-onset pneumonia in the aging Japanese population: A multicenter prospective study. DOI: 10.1371/journal.pone.0122247, PLoS One. 10: e0122247, 2015

呼吸器感染症感染アウトブレーク調査

1.

Kuroki T, Ishida M, Suzuki M, Furukawa I, Ohya H, Watanabe Y, Konnai M, Aihara Y, Chang B, Ariyoshi K, Oishi K, Ohnishi M, Morimoto K*. Outbreak of Streptococcus pneumoniae serotype 3 pneumonia in extremely elderly people in a nursing home unit in Kanagawa, Japan, doi: 10.1111/jgs.12863. 2013. J Am Geriatr Soc. 62, 1197-1198 (2014)

2.

Miyahara R, Suzuki M, Morimoto K, Chang B, Yoshida S, Yoshinaga S, Kitamura M, Chikamori M, Oishi K, Kitamura T, Ishida M. Nosocomial Outbreak of Upper Respiratory Tract Infection With β-Lactamase-Negative Ampicillin-Resistant Nontypeable Haemophilus influenzae. doi: 10.1017/ice.2018.56. Infect Control Hosp Epidemiol. 39:652-659, (2018)

高齢者肺炎球菌保菌研究

1.

Yasuda I, Suzuki M, Maeda H, Terada M, Sando E, Ng CFS, Otomaru H, Yoshida LM, Morimoto K.Respiratory virus detection in the upper respiratory tract of asymptomatic, community-dwelling older people. BMC Infect Dis. 22:411(2022)

2.

Yasuda I, Suzuki M, Dhoubhadel BG, Terada M, Satoh A, Sando E, Hiraoka T, Kurihara M, Matsusaka N, Kawahara F, Ariyoshi K, Morimoto K*. The low carriage prevalence of pneumococcus among community-dwelling older people: A cross-sectional study in Japan, doi: 10.1016/j.vaccine.2020.03.033. Vaccine. 38: 3752-3758, (2020)

JPAVE/JPAVE2研究

1.

Maeda H, Ito I, Sando E, Hamano N, Shirata M, Gopal Dhoubhadel B, Ntiamoah DO, Oi I, Nishioka K, Fujii H, Okamura K, Inoue T, Yamada T, Niibayashi S, Tsukino M, Fujii Y, Tsuchiya M, Nakahara Y, Hasegawa Y, Nakagawa A, Sugita T, Ito A, Sakai N, Kaji Y, Toyoda Y, Urata T, Asoh N, Nishiyama A, Yagiuchi A, Morikawa T, Ushiki A, Ishida M, Morimoto K, Serotype distribution among adults with community-acquired pneumococcal pneumonia in Japan between 2019 and 2022: Amulticenter observational study. Hum Vaccin Immunother. in press, 2025

2.

Maeda H, Gopal Dhoubhadel B, Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K, Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020. DOI: 10.1016/j.vaccine.2022.07.041, Vaccine. 40:5504-5512, 2022

3.

Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE). DOI: 10.1016/j.vaccine.2019.04.009, Vaccine. 37:2687-2693, 2019

その他

1.

Maeda H, Morimoto K. Global distribution and characteristics of pneumococcal serotypes in adults. DOI: 10.1080/21645515.2025.2469424, Hum Vaccin Immunother. 21:2469424, 2025

2.

Morimoto K, Masuda S. Pneumococcal vaccines for prevention of adult pneumonia. DOI: 10.1016/j.resinv.2024.12.007, Respir Investig. ;63:96-101, 2025

3.

Dhoubhadel BG, Sawada I, Shrestha D, Fukuya Y, Raya GB, Nébié EI, Hayashi Y, Pasakhala R, Motoi Suzuki, Morimoto K, Parry CM, Ariyoshi K. A description of a pre-emptive typhoid Vi capsular polysaccharide vaccination campaign after the 2015 earthquake in Nepal and vaccine effectiveness evaluation. DOI: 10.1186/s41182-024-00580-w, Trop Med Health. 52:14, 2024

4.

Yamashita Y, Yasuda I, Tanaka T, Ikeda T, Terada M, Takaki M, Tsuchihashi Y, Asoh N, Ohara Y, Enany S, Kobayashi H, Matsumoto S, Morimoto K. Antigen-specific cytokine profiles for pulmonary Mycobacterium avium complex disease stage diagnosis. DOI: 10.3389/fimmu.2023.1222428, Front Immunol.14:1222428, 2023

5.

Yasuda I, Suzuki M, Maeda H, Terada M, Sando E, Ng CFS, Otomaru H, Yoshida LM, Morimoto K. Respiratory virus detection in the upper respiratory tract of asymptomatic, community-dwelling older people. DOI: 10.1186/s12879-022-07355-w, BMC Infect Dis. 22:411, 2022

6.

Ito H, Yamashita Y, Tanaka T, Takaki M, Le MN, Yoshida LM, Morimoto K. Cigarette smoke induces endoplasmic reticulum stress and suppresses efferocytosis through the activation of RhoA. DOI: 10.1038/s41598-020-69610-x, Sci Rep. 10:12620, 2021